European Approval for Eye Care Drug Jetrea

by Raja Nandhini on  March 19, 2013 at 7:08 AM Drug News   - G J E 4
Pharmaceutical company, ThromboGenics, has received the green signal from the European Commission for its drug, Jetrea (ocriplasmin).
 European Approval for Eye Care Drug Jetrea
European Approval for Eye Care Drug Jetrea

Jetrea is used in treating vitreomacular traction (VMT), an age related disorder in the eye. VMT causes holes in the macula, an important area in the retina responsible for vision.

It is estimated that 250,000-300,000 patients in Europe alone suffer from this condition and surgery at an advanced stage is the major treatment option available currently. However, a single injection of Jetrea, the need for surgery could be avoided in many cases.

ThromboGenics holds the rights to market the drug in USA while its partner, Novartis would market the drug in Europe through its eye care division, Alcon.

Source: Medindia

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like